GeneDx Holdings Statistics

Total Valuation

GeneDx Holdings has a market cap or net worth of $1.68 billion. The enterprise value is $1.64 billion.

Market Cap	1.68B
Enterprise Value	1.64B

Important Dates

The last earnings date was Wednesday, April 30, 2025, before market open.

Earnings Date	Apr 30, 2025
Ex-Dividend Date	n/a

Share Statistics

GeneDx Holdings has 28.53 million shares outstanding. The number of shares has increased by 6.20% in one year.

Current Share Class	28.53M
Shares Outstanding	28.53M
Shares Change (YoY)	+6.20%
Shares Change (QoQ)	+1.31%
Owned by Insiders (%)	1.55%
Owned by Institutions (%)	67.88%
Float	18.50M

Valuation Ratios

PE Ratio	n/a
Forward PE	47.48
PS Ratio	4.90
Forward PS	4.55
PB Ratio	6.54
P/TBV Ratio	16.45
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	4.96
EV / EBITDA	180.46
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.25, with a Debt / Equity ratio of 0.45.

Current Ratio	3.25
Quick Ratio	2.95
Debt / Equity	0.45
Debt / EBITDA	7.11
Debt / FCF	n/a
Interest Coverage	-4.03

Financial Efficiency

Return on equity (ROE) is -16.61% and return on invested capital (ROIC) is -2.22%.

Return on Equity (ROE)	-16.61%
Return on Assets (ROA)	-1.84%
Return on Invested Capital (ROIC)	-2.22%
Return on Capital Employed (ROCE)	-3.29%
Revenue Per Employee	$330,143
Profits Per Employee	-$38,576
Employee Count	1,000
Asset Turnover	0.79
Inventory Turnover	9.45

Taxes

In the past 12 months, GeneDx Holdings has paid $186,000 in taxes.

Income Tax	186,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +184.34% in the last 52 weeks. The beta is 2.04, so GeneDx Holdings's price volatility has been higher than the market average.

Beta (5Y)	2.04
52-Week Price Change	+184.34%
50-Day Moving Average	89.90
200-Day Moving Average	68.95
Relative Strength Index (RSI)	34.11
Average Volume (20 Days)	1,664,636

Short Selling Information

The latest short interest is 3.57 million, so 12.52% of the outstanding shares have been sold short.

Short Interest	3.57M
Short Previous Month	3.25M
Short % of Shares Out	12.52%
Short % of Float	19.30%
Short Ratio (days to cover)	4.33

Income Statement

In the last 12 months, GeneDx Holdings had revenue of $330.14 million and -$38.58 million in losses. Loss per share was -$1.41.

Revenue	330.14M
Gross Profit	215.47M
Operating Income	-12.40M
Pretax Income	-118.33M
Net Income	-38.58M
EBITDA	9.08M
EBIT	-12.40M
Loss Per Share	-$1.41

Full Income Statement

Balance Sheet

The company has $159.16 million in cash and $114.84 million in debt, giving a net cash position of $44.32 million or $1.55 per share.

Cash & Cash Equivalents	159.16M
Total Debt	114.84M
Net Cash	44.32M
Net Cash Per Share	$1.55
Equity (Book Value)	257.41M
Book Value Per Share	9.02
Working Capital	156.28M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$1.90 million and capital expenditures -$11.18 million, giving a free cash flow of -$13.08 million.

Operating Cash Flow	-1.90M
Capital Expenditures	-11.18M
Free Cash Flow	-13.08M
FCF Per Share	-$0.46

Full Cash Flow Statement

Margins

Gross margin is 65.27%, with operating and profit margins of -3.76% and -11.68%.

Gross Margin	65.27%
Operating Margin	-3.76%
Pretax Margin	-11.63%
Profit Margin	-11.68%
EBITDA Margin	2.75%
EBIT Margin	-3.76%
FCF Margin	n/a

Dividends & Yields

GeneDx Holdings does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-6.20%
Shareholder Yield	-6.20%
Earnings Yield	-2.29%
FCF Yield	-0.78%

Analyst Forecast

The average price target for GeneDx Holdings is $81.33, which is 37.85% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$81.33
Price Target Difference	37.85%
Analyst Consensus	Strong Buy
Analyst Count	6
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on May 4, 2023. It was a reverse split with a ratio of 0.030303:1.

Last Split Date	May 4, 2023
Split Type	Reverse
Split Ratio	0.030303:1

Scores

GeneDx Holdings has an Altman Z-Score of 1.31 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.31
Piotroski F-Score	5